
													
															
															Year
															DEALS // DEV.
															Country
															
															Therapeutic Area
															Study Phase
															Deal Type
															Product Type
															Dosage Form
															Lead Product
															Target

 Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass.                    
Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.
Lead Product(s) : Undisclosed
Therapeutic Area : Neurology
Study Phase : Discovery
Sponsor : Jiangsu Nhwa Pharmaceutical
Deal Size : Undisclosed
Deal Type : Agreement
Complix Discovery Development Agreement Jiangsu Develop Alphabody Therapeutics
Details : Under the terms of the agreement, Complix has granted an exclusive license to Nhwa to develop, manufacture and commercialize the CPABs resulting from this collaboration in Greater China.
Product Name : Undisclosed
Product Type : Undisclosed
Upfront Cash : Undisclosed
July 28, 2021
Lead Product(s) : Undisclosed
Therapeutic Area : Neurology
Highest Development Status : Discovery
Sponsor : Jiangsu Nhwa Pharmaceutical
Deal Size : Undisclosed
Deal Type : Agreement

 Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass.                    
Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.
Lead Product(s) : Undisclosed
Therapeutic Area : Oncology
Study Phase : Preclinical
Sponsor : Undisclosed
Deal Size : Inapplicable
Deal Type : Inapplicable
Complix and VIB Publish Pioneering Study on Cell-Penetrating Alphabodies in Science Advances
Details : The proof-of-concept study showed the potential of Cell-Penetrating Alphabodies to efficiently penetrate the cancer cell membrane, disrupt an intracellular protein-protein interface, and cause an anti-tumor effect upon in vivo administration in relevant ...
Product Name : Undisclosed
Product Type : Undisclosed
Upfront Cash : Inapplicable
March 31, 2021
Lead Product(s) : Undisclosed
Therapeutic Area : Oncology
Highest Development Status : Preclinical
Sponsor : Undisclosed
Deal Size : Inapplicable
Deal Type : Inapplicable

 Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass.                    
Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.
Lead Product(s) : Undisclosed
Therapeutic Area : Oncology
Study Phase : Preclinical
Sponsor : I-Mab Biopharma
Deal Size : Undisclosed
Deal Type : Agreement
Details : Under the terms of the agreement, Complix will use its proprietary Alphabody platform to deliver Cell Penetrating Alphabodies (CPABs) against two immuno-oncology intracellular targets.
Product Name : Undisclosed
Product Type : Undisclosed
Upfront Cash : Undisclosed
March 10, 2021
Lead Product(s) : Undisclosed
Therapeutic Area : Oncology
Highest Development Status : Preclinical
Sponsor : I-Mab Biopharma
Deal Size : Undisclosed
Deal Type : Agreement
